Ozempic and Gastroparesis: Who Should Be Monitored?
Latest update (2026-01)
- FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health to Targeted Risk: The Legacy of Mass Production
If you or a loved one has experienced persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance research have established that drug-induced motility disorders require careful evaluation of individual risk factors. This page summarizes the current evidence on Ozempic-associated gastroparesis, including who may need monitoring and what symptoms to watch for.
Bridging to Ozempic: Pharmacological Mechanism and Gastrointestinal Risks
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacological action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The mechanistic link between Ozempic and gastroparesis is rooted in the drug's effect on GLP-1 receptors, which inhibit gastric motility and can lead to prolonged gastric retention, potentially exacerbating or unmasking gastroparesis in susceptible individuals. Clinical trial data from the Ozempic prescribing information document a significantly higher incidence of gastrointestinal adverse reactions compared to placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in the Ozempic groups (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Evidence of Gastroparesis Risk and Warning Adequacy
While these data do not specifically diagnose gastroparesis, the symptoms overlap significantly with the clinical presentation of gastroparesis, and the drug's known effect on gastric emptying provides a plausible mechanistic pathway. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported, and that caution is advised in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly warn of gastroparesis as a distinct adverse reaction. Instead, it groups gastrointestinal symptoms under general adverse reactions. This may leave patients and healthcare providers unaware of the potential for severe, persistent gastric motility issues that could meet the clinical definition of gastroparesis. For affected patients, the lack of a specific warning could impact informed consent and the ability to recognize early signs of gastroparesis, potentially delaying diagnosis and treatment.
Settlement Considerations for New York Patients
Settlement-related considerations for patients who have developed gastroparesis after using Ozempic involve several factors. First, the timeline between exposure and documented harm is critical. Clinical trial data indicate that gastrointestinal adverse reactions often occur during dose escalation, but the onset of gastroparesis may be delayed or cumulative. Patients who experienced persistent nausea, vomiting, or abdominal pain after starting Ozempic and were later diagnosed with gastroparesis may have a claim if they can demonstrate that the drug caused or contributed to their condition. Second, the adequacy of warnings is central to product liability claims. If the manufacturer failed to adequately warn about the risk of gastroparesis, patients may argue that they were not properly informed. Third, the severity and duration of symptoms, as well as the need for medical interventions such as hospitalization, nutritional support, or prokinetic medications, can influence settlement amounts. Patients in New York, where legal actions may be consolidated, should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances. In summary, the evidence from clinical trials shows a clear increase in gastrointestinal adverse reactions with Ozempic use, including symptoms consistent with gastroparesis. The mechanistic link through delayed gastric emptying is well-established. However, the prescribing information does not explicitly warn of gastroparesis, which may affect patient awareness and legal claims. For affected individuals, the timeline of symptom onset relative to drug initiation and the adequacy of warnings are key factors in potential settlement considerations. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Ozempic and gastroparesis?
Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to gastrointestinal symptoms like nausea, vomiting, and bloating. These symptoms overlap with gastroparesis, a condition of delayed gastric emptying. Clinical trials show a significantly higher incidence of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Does the Ozempic label warn about gastroparesis?
No, the prescribing information does not explicitly warn of gastroparesis as a distinct adverse reaction. It groups gastrointestinal symptoms under general adverse reactions, which may leave patients and healthcare providers unaware of the potential for severe, persistent gastric motility issues (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
What factors affect an Ozempic gastroparesis settlement in New York?
Key factors include the timeline between Ozempic use and gastroparesis diagnosis, the adequacy of warnings, and the severity of symptoms requiring medical intervention. Patients should consult a New York attorney experienced in pharmaceutical litigation to evaluate their case.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.